Biomineralized engineered <i>Lactococcus lactis</i>-based in situ vaccination enhances antitumor immunity via sequential activation of chemo-immunotherapy.

ABSTRACT:

Background

Combining chemotherapy with immunotherapy is a promising strategy to enhance in situ immunity by increasing antigen exposure and inflammation in the tumor microenvironment (TME). However, the inconvenience of separate administration and the randomness of delivery can diminish the synergistic effect of these treatments. An efficient co-delivery system to optimize chemo-immunotherapy is urgently needed.

Methods

We have previously developed an engineered Lactococcus lactis (FOLactis) expressing Flt3L and OX40L to activate immune cells. Here, we biomineralized FOLactis by magnesium (Mg²⁺)-based frameworks (Mg-metal-organic frameworks (MOFs)) loaded with cisplatin and vincristine (D&V@FOLactis) to achieve sequential activation of in situ antitumor eff

SUBMITTER: Chen Z 

PROVIDER: S-EPMC12359421 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature